Oral Cabotegravir + Oral Rilpivirine versus Efavirenz + 2 NRTI’s

LATTE Study
Oral Cabotegravir + Oral Rilpivirine versus Efavirenz + 2 NRTI’s
LATTE Study: Design

• **Background**: Phase 2b, randomized, partially blinded study done at multiple centers in the U.S. and Canada

• **Inclusion Criteria**
  - Age ≥18 years
  - Antiretroviral-naïve
  - HIV RNA >1,000 copies/mL
  - CD4 count >200 cells/mm³
  - CrCl >50 mL/min
  - No hepatitis B
  - No significant transaminitis

Oral Cabotegravir + Oral Rilpivirine versus Efavirenz + 2 NRTI's: LATTE Study: Results

**Induction**

- Oral Cabotegravir + 2NRTIs: 86 (156/181)
- Oral Cabotegravir + Oral Rilpivirine: 74 (46/62)
- Efavirenz + 2NRTIs: 74 (46/62)

**Maintenance**

- Oral Cabotegravir + 2NRTIs: 82 (149/181)
- Oral Cabotegravir + Oral Rilpivirine: 71 (44/62)
- Efavirenz + 2NRTIs: 76 (39/62)

*Cabotegravir data is composite of all cabotegravir doses

Oral Cabotegravir + Oral Rilpivirine versus Efavirenz + 2 NRTI’s
LATTE Study: Results


*During induction phase cabotegravir administered with investigator chosen 2NRTIs
Conclusions: “Cabotegravir plus dual NRTI therapy had potent antiviral activity during the induction phase. As a two drug maintenance therapy, cabotegravir plus rilpivirine provided antiviral activity similar to efavirenz plus dual NRTIs until the end of week 96. Combined efficacy and safety results lend support to our selection of oral cabotegravir 30 mg once a day for further assessment. LATTE precedes studies of the assessment of long-acting injectable formulations of both drugs as a two-drug regimen for the treatment of HIV-1 infection.”
The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,000,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.